Inappropriate data and measures lead to questionable conclusions by Spielmans, Glen I. et al.
LETTERS TO THE EDITOR
Inappropriate Data and Measures
Lead to Questionable Conclusions
I n recent articles, Gibbons and colleagues
1,2 con-
cluded that antidepressants lowered suicidality rela-
tive to placebo among adult patients while demon-
strating no difference in suicidality among youths; they
further concluded that antidepressants possessed ro-
bust efficacy vs placebo. However, there are several prob-
lems with the underlying data and their choice of sui-
cidality measures.
Though their article purported to include data regard-
ing patients withmajor depressive disorder, not all trials
included patients with a primary diagnosis of depres-
sion. For example, in the LYAQ fluoxetine trial, partici-
pants either (1)metDSM-IV criteria for attention-deficit/
hyperactivity disorder and had concurrent anxious/
depressive symptoms or (2) met criteria for an anxiety
or depressive disorder and had concurrent attention-
deficit/hyperactivity disorder symptoms. Further, all par-
ticipants taking fluoxetine were also taking atomox-
etine hydrochloride, rendering the trial incapable of
assessing potential fluoxetine-related suicidality; thus, this
study does not provide evidence regarding either the ef-
ficacy or safety of fluoxetine relative to placebo.3Wewould
have gladly combed through descriptions of the remain-
ing studies to assess for similar problems, but most of
them are difficult or impossible to obtain. Readers should
not have to attempt a search ofmanufacturer clinical trial
databases, which are far from inclusive, to find basic de-
scriptions of included studies; at the very least, for each
included trial, a clearer description of participants’ di-
agnoses, concurrent treatment, reports of suicide-
related events, and change on depression rating scales is
needed to better understand the nature of the data un-
derlying the claims of Gibbons et al.
TheGibbons et al data set included adult trials of fluox-
etine and venlafaxine but data from youth taking venla-
faxine were not included. This unexplained maneuver
clearly biases their analyses given that clinical trial data
on venlafaxine found a substantially elevated risk of sui-
cidality relative to placebo. The original venlafaxine pub-
lication found that 11 of 182 patients receiving venla-
faxine experienced suicide-related events comparedwith
1 patient of 179 receiving placebo.4 After these data were
carefully recoded by a second group of researchers, the
numbers changed to 8 of 182 patients receiving venla-
faxine compared with 0 of 179 receiving placebo.5 Either
way, venlafaxine was associated with increased suicid-
ality in adolescents, yet this important data set was in-
appropriately excluded.
Gibbons et al do not provide actual data on suicide
attempts and suicides broken down by drug vs placebo.
Perhaps the closest tabulation of such data for youth can
be found in the Bridge et al meta-analysis5 of suicide ide-
ation, attempts, and preparatory action, which gener-
ated the following numbers: 17 events of 287 partici-
pants receiving fluoxetine compared with 11 of 289
receiving placebo and 8 of 182 receiving venlafaxine com-
pared with 0 of 179 receiving placebo. Thus, including
the 2 drugs examined by Gibbons et al, the rate of sui-
cidality while receiving the drug is 5.33% compared with
2.35%while receiving placebo, a relative risk of 2.27. This
comes as no surprise given that multiple meta-analyses
have found increased rates of suicidal events while
receiving antidepressants relative to placebo among
youth.5,6
The choice of primary outcome for the Gibbons et al
suicidality study, scores on theChildren’s DepressionRat-
ing Scale (CDRS) and Hamilton Depression Rating Scale
(HAM-D) suicidality items, is problematic. TheCDRS and
HAM-D are primarily used to detect a signal of treat-
ment efficacy; neitherWyeth nor Lilly designed their trials
with the idea of systematically assessing potential treat-
ment-emergent suicidality. These items are low-
threshold measures, potentially generating background
noise, leading to a diminished ability to detect the true
signal of less common butmore troubling suicidal events.
Changes in rating scale scores regarding suicidality are
surely less meaningful than actual reports of suicide-
related adverse events, particularly those that have been
independently coded by experts in the field of suicide re-
search, as was the case in the aforementioned meta-
analyses.5,6 While statistical power may be increased by
the use of a rating scale item completed atmultiple points
by hundreds of participants, such power is meaningless
and potentially misleading if it obscures the detection of
true suicidal events. The director of the Food and Drug
Administration Psychiatry Products Division, Thomas
Laughren, MD, expressed that relying on rating scales to
detect suicidality “turned out not to be very helpful.”7
Robert Temple, MD, the director of the Office of Medi-
cal Policy at the Center for Drug Evaluation and Re-
search at the Food and Drug Administration, also noted
that a depression rating scale is “not where it shows up,”
referring to the signal of suicidality among youth taking
antidepressants.8
For venlafaxine in youth depression, the effect size on
theCDRS in favor of drug is ameager d=0.14, falling short
of the conventional definition of even a small treatment
effect.5 In addition, Gibbons et al excluded fluoxetine
study HCCJ, apparently because it did not use the CDRS.
However, on the HAM-D, the change shown by youth
taking fluoxetine was only 11% greater than the change
shown by youth taking placebo.9 We are aware of only 1
Wyeth-sponsored venlafaxine trial with depressed geri-
atric patients; it found that treatment with either venla-
faxine or fluoxetine was no more effective than pla-
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cebo.10 If these data are added to the mix, the combined
efficacy of venlafaxine and fluoxetine for youth be-
comesmuch less impressive and the alreadymiddling ef-
ficacy data regarding the geriatric population likely be-
come yet less favorable.
The reporting of the advantage for fluoxetine over pla-
cebo exaggerates its benefits. A drop of 15.96 for pla-
cebo and 20.58 for fluoxetine was reported as a 29%
greater improvement for fluoxetine; this could equally
well have been reported as placebo achieving 78% of the
change that occurredwhile receiving fluoxetine. The cat-
egories of response (50% reduction inCDRS-R score) and
remission (CDRS-R score28) were arbitrarily created
out of a continuousmeasure, as demonstrated by the im-
plausible finding that remission was more frequent than
response. A sensitivity analysis should have been car-
ried out to see if the differences survived different defi-
nitions of response and remission. We are also puzzled
by the reported 5.7% response rate while receiving pla-
cebo in youth fluoxetine trials. Using the Gibbons et al
criterion for response, the reported placebo response rate
was 16.8% in the HCJE study and approximately 18% in
the X065 study (extrapolated from the Figure in the clini-
cal trial report).9 Data from the LYAQ trial are irrel-
evant. Study reports from the Treatment for Adoles-
cents With Depression Study did not use the Gibbons et
al response criterion, but the response rate on the Clini-
cal Global Impression scale for placebo was 34.8%.11 Re-
sponse rates were not reported in HCCJ, but the average
participant receiving placebo improved by greater than
50% on the HAM-D-21.9 Though not mentioned in their
article, Gibbons et al selected the youth antidepressant
trials with the lowest placebo response rate, helping to
maximize apparent drug-placebo differences.12 The ver-
dict on the efficacy of antidepressants in youth remains
unchanged; the overall effect size of d=0.20 on clinician-
rated depressive symptoms—and likely less on self-
report measures—is unimpressive.5
While we applaud the use of patient-level data to ex-
amine the potential relationship between initial severity
and treatment outcome, the exclusion of data from rel-
evant trials and inclusion of data from inappropriate trials
along with the use of a poor measure to detect suicidal-
ity renders the conclusions of Gibbons et al question-
able at best. We hope that a more comprehensive, ap-
propriate, clearly described data set may help to address
important questions of antidepressant safety and effi-
cacy.
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In reply
We appreciate Spielmans and colleagues’ interest in our ar-
ticle; however, their concerns about the data in our article
are unfounded.
Glen I. Spielmans, PhD
Jon Jureidini, PhD, MBBS, FRANZCP
David Healy, MD
Robert Purssey, MBBS, FRANZCP
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Spielmans and colleagues state that study LYAQ in-
cluded atomoxetine as a treatment and should have been ex-
cluded. In fact, the first 2 active treatment visits did not in-
clude atomoxetine and our analysis of the data from this study
was restricted to this period (days 1-42 postbaseline de-
pending on the subject). Furthermore, although patients in
this study had comorbidities including attention-deficit/
hyperactivity disorder, the majority (81%) of patients had
a depressive disorder. As such, our inclusion of this study
was scientifically appropriate.
Spielmans and colleagues suggest that our failure to in-
clude youth studies of venlafaxine in our research synthe-
sis is an “unexplained maneuver” that “clearly biases their
analyses.”We did not have access to pediatric data for ven-
lafaxine. The primary focus of our article was on fluox-
etine. The adult venlafaxine data were used to determine the
extent to which our overall findings for adults only gener-
alized to other antidepressants. Our article is clear that for
elderly individuals and youth, our results are for fluoxetine
only and that we had not determined whether these results
generalize to other antidepressants for the same age groups.
With respect to the use of rating scales tomeasure suicide-
related events, there are both strengths andweaknesses. The
strength is that these are prospective ratings by trained cli-
nicians and not spontaneous reports that are subject to a va-
riety of ascertainment biases.1 Furthermore, our analysis
preserved the ordinal nature of the suicide risk scale, cor-
rectly placing suicidal behavior at a higher level in the hi-
erarchy than suicidal thoughts. Spielmans and colleagues’
crude odds ratios treat suicidal thoughts and behavior equally,
which is a less informative analysis. Their analysis and re-
lated meta-analyses also ignore the timing of these events,
ignoring the fact that as a whole suicide risk decreases sub-
stantially over time regardless of intervention status. Cur-
rent studies havemore complete suicide rating scale data that
permit improved prospective quantification of suicide risk.2
Spielmans and colleagues cite an effect size of 0.14 for
youth venlafaxine studies, based on a meta-analysis of end
points without the benefit of complete longitudinal data as
we used. Our exclusion of study HCCJ is unfortunate but at
the time necessary because the statistical method used in our
research synthesis uses the samemeasure in all studies. Ad-
ditional work is under way to harmonize these measures.
Spielmans and colleagues cite a variety of response rates
from various sources from various selected trials or meta-
analyses, none of which used themore rigorous research syn-
thesis provided in our article. Extrapolating values from fig-
ures that ignore missing data is no substitute for the more
complete longitudinal analysis provided in our article. The
observed effect of fluoxetine on depression in youth is im-
pressive and important to public health. Whether this ben-
efit generalizes to other antidepressants remains an open sci-
entific question.
Author Affiliations: Departments of Medicine, Health
Studies, and Psychiatry (Dr Gibbons) and Center for
Health Statistics (Drs Gibbons, Brown, and Hur), Uni-
versity of Chicago, and Department of Psychiatry, Uni-
versity of Illinois at Chicago (Dr Davis), Chicago, and
Center forMedication Safety, Pharmacy Benefit Manage-
ment Services, Hines Veterans Affairs Hospital, Hines (Dr
Hur); Prevention Science andMethodology Group, Cen-
ter for Family Studies, Department of Epidemiology and
Public Health, University of Miami, Miami, Florida (Dr
Brown); andDepartment ofMolecular Imaging andNeu-
ropathology,NewYork State Psychiatric Institute andDe-
partment of Psychiatry, Columbia University College of
Physicians and Surgeons, New York (Dr Mann).
Correspondence: Dr Gibbons, University of Chicago,
5841 S Maryland Ave, MC 2007, OfficeW260, Chicago,
IL 60637 (rdg@uchicago.edu).
Conflict of Interest Disclosures:Dr Gibbons has served
as an expert witness for the US Department of Justice,
Wyeth, and Pfizer Pharmaceuticals in cases related to an-
tidepressants and anticonvulsants and suicide. Dr Brown
directed a suicide prevention program at the University
of South Florida that received funding from JDS Phar-
maceuticals. DrMann has received research support from
GlaxoSmithKline and Novartis.
Funding/Support: This work was supported by grants
MH062185 (Dr Mann), R56 MH078580 (Drs Gibbons
and Brown),MH8012201 (Drs Gibbons and Brown), and
MH040859 (Dr Brown) from the National Institute of
MentalHealth and grant 1U18HS016973 from theAgency
for Healthcare Research and Quality (Dr Gibbons).
1. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classifi-
cation Algorithm of Suicide Assessment (C-CASA): classification of suicidal
events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am
J Psychiatry. 2007;164(7):1035-1043.
2. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Cur-
rier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide
Severity Rating Scale: initial validity and internal consistency findings from
three multisite studies with adolescents and adults. Am J Psychiatry. 2011;
168(12):1266-1277.
Suicide Risk and Efficacy
of Antidepressant Drugs
I n their reports
1,2 addressing the black box warning
about antidepressant drugs and suicide risk, Gib-
bons et al conducted risk/efficacy reanalyses of se-
lected data sets. They concluded that
no significant effects of treatment on suicidal thoughts and be-
havior were found. . . . No evidence of increased suicide risk
was observed in youths receiving active medication.1(p580)
These conclusions are unsound. The data are con-
taminated by trial LYAQ,2-4 which studied atomoxetine
hydrochloridewith orwithout fluoxetine in patients with
attention-deficit/hyperactivity disorder with depressive
or anxious symptoms. Less than half had major depres-
sion diagnoses4; pretreatment depression scoresmatched
posttreatment scores in the other youth studies.2 These
problematic details were not addressed. By lack of con-
forming diagnoses and design, LYAQ outright invali-
dates the aggregate analyses.
The key adverse outcomewas termed suicide risk, but
Gibbons et al did not measure suicide risk. They im-
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